Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2004
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/27119
Acceso en línea:
http://dx.doi.org/10.1136/ard.2004.029694
https://repository.urosario.edu.co/handle/10336/27119
Palabra clave:
Lupus erythematosus
systemic
Drug therapy
Rheumatic diseases
Sjogren's syndrome
Rights
License
Abierto (Texto Completo)
id EDOCUR2_29ab6f58735b8735db1311db6567d5cb
oai_identifier_str oai:repository.urosario.edu.co:10336/27119
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling cf46f3e1-d879-434f-8edc-b92a80c6000214eeeeef-0dd9-4d97-ade8-3c4ea1314518b42918cf-d88a-4c7d-8420-36e1a7903e27363a398e-e9c8-42e8-bf3b-ad3017384726194747786002020-08-19T14:41:03Z2020-08-19T14:41:03Z2004-11-14Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjo¨gren’s syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.application/pdfhttp://dx.doi.org/10.1136/ard.2004.029694ISSN: 0003-4967EISSN: 1468-2060https://repository.urosario.edu.co/handle/10336/27119engEuropean League Against RheumatismBMJ Publishing920No. 6913Annals of the Rheumatic DiseasesVol. 64Annals of the Rheumatic Diseases, ISSN: 0003-4967;EISSN: 1468-2060, Vol.64, No.6 (Jun 2005); pp. 913-920https://ard.bmj.com/content/annrheumdis/64/6/913.full.pdfAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2Annals of the Rheumatic Diseasesinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURLupus erythematosussystemicDrug therapyRheumatic diseasesSjogren's syndromeTolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseasesTolerancia y eficacia a corto plazo de rituximab en 43 pacientes con enfermedades autoinmunes sistémicasarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Gottenberg, J-EGuillevin, LLambotte, OCombe, BAnaya, Juan-Manuel10336/27119oai:repository.urosario.edu.co:10336/271192021-08-10 22:50:34.1https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
dc.title.TranslatedTitle.spa.fl_str_mv Tolerancia y eficacia a corto plazo de rituximab en 43 pacientes con enfermedades autoinmunes sistémicas
title Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
spellingShingle Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Lupus erythematosus
systemic
Drug therapy
Rheumatic diseases
Sjogren's syndrome
title_short Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
title_full Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
title_fullStr Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
title_full_unstemmed Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
title_sort Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
dc.subject.keyword.spa.fl_str_mv Lupus erythematosus
systemic
Drug therapy
Rheumatic diseases
Sjogren's syndrome
topic Lupus erythematosus
systemic
Drug therapy
Rheumatic diseases
Sjogren's syndrome
description Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjo¨gren’s syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.
publishDate 2004
dc.date.created.spa.fl_str_mv 2004-11-14
dc.date.accessioned.none.fl_str_mv 2020-08-19T14:41:03Z
dc.date.available.none.fl_str_mv 2020-08-19T14:41:03Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv http://dx.doi.org/10.1136/ard.2004.029694
dc.identifier.issn.none.fl_str_mv ISSN: 0003-4967
EISSN: 1468-2060
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/27119
url http://dx.doi.org/10.1136/ard.2004.029694
https://repository.urosario.edu.co/handle/10336/27119
identifier_str_mv ISSN: 0003-4967
EISSN: 1468-2060
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 920
dc.relation.citationIssue.none.fl_str_mv No. 6
dc.relation.citationStartPage.none.fl_str_mv 913
dc.relation.citationTitle.none.fl_str_mv Annals of the Rheumatic Diseases
dc.relation.citationVolume.none.fl_str_mv Vol. 64
dc.relation.ispartof.spa.fl_str_mv Annals of the Rheumatic Diseases, ISSN: 0003-4967;EISSN: 1468-2060, Vol.64, No.6 (Jun 2005); pp. 913-920
dc.relation.uri.spa.fl_str_mv https://ard.bmj.com/content/annrheumdis/64/6/913.full.pdf
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv European League Against Rheumatism
BMJ Publishing
dc.source.spa.fl_str_mv Annals of the Rheumatic Diseases
institution Universidad del Rosario
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167545607880704